January 14, 2022
[UPDATE]: Visit here for the recording and to read a summary.
On Wednesday, January 19, AVAC and partners shared critical insights and lessons from oral PrEP programs in Kenya, South Africa, and Zimbabwe. Learning from these efforts, and other key lessons from oral PrEP introduction to date, is essential to faster, smarter and more affordable rollout of future HIV prevention products, including the Dapivirine Vaginal Ring and injectable cabotegravir. These lessons are built on more than six years of analysis and collaboration with partners and reflect urgent priorities for the field. The world cannot afford to make the same mistakes twice as a growing number of tools for prevention gain regulatory approval.
Click here to watch Oral PrEP Implementation and Implications for Next Generation PrEP. You’ll hear Saiqa Mullick of WitsRHI, Joseph Murungu of Pangaea Zimbabwe AIDS Trust (PZAT), and Daniel Were of Jhpiego discuss what has worked and what must change to transform options into choices, to finally reach the targets that will end the epidemic of HIV.
These insights offer a unique opportunity to fulfill the potential of HIV biomedical prevention, demonstrate the impact of informed choice, and realize the full benefits of increasing the use of HIV prevention among those who need it most. As additional PrEP options come to market, they could transform the landscape of HIV prevention—offering more personalized options, increasing the number of PrEP users, and ultimately contributing to lower HIV incidence. These products must be accessible, acceptable and used effectively by those who need them.
This webinar follows the important discussion AVAC convened yesterday, where leading voices in the field of HIV prevention identified their priorities in 2022. Check out the recording of Ups & Downs in the Field: Setting an agenda together for 2022, and watch the January 19th discussion to focus on next steps for these priorities on getting rollout right in 2022.